Hoth Therapeutics (HOTH)
(Delayed Data from NSDQ)
$1.18 USD
-0.05 (-4.07%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $1.17 -0.01 (-0.85%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HOTH 1.18 -0.05(-4.07%)
Will HOTH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HOTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOTH
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
HOTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for HOTH
Hoth Therapeutics files to sell 5.03M shares of common stock for holders
Hoth Therapeutics files to sell 5.03M shares of common stock for holders
Promising Preclinical Alzheimer’s Candidate and Diverse Pipeline Bolster Hoth Therapeutics’ Buy Rating
Hoth Therapeutics price target raised by 50c at EF Hutton, here's why
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds